Laurus Labs Ltd - Share Price
LAURUSLABS
Laurus Labs LtdFinancials
Laurus Labs LtdNews & Updates
Laurus Labs to manufacture Molnupiravir, oral COVID-19 medication in association with MPP
Jan 21,2022 12:44 PM
The company is happy to sign an agreement to manufacture the oral Covid-19 antiviral medication, being an urgent need of the hour,
Meeting Type
Meeting Date
| Resolution Type | Description Of Resolution | IiAS Recommendation |
|---|
Peer Comparison
| Name | LTP | PE | Mar Cap | NP Qtr | Div. Yld | Sales Qtr | BV |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | 884.00 | 108.74 | 194,118.20 | 809.07 | 0.93 | 4,120.93 | 113.47 |
| Divis Laboratories Ltd | 3,850.00 | 52.64 | 110,935.34 | 606.39 | 0.48 | 1,967.86 | 372.89 |
| Dr Reddys Laboratories Ltd | 4,400.00 | 46.28 | 74,862.73 | 449.00 | 0.56 | 3,809.50 | 1,049.62 |
| Cipla Ltd | 950.50 | 26.03 | 69,942.44 | 782.37 | 0.58 | 3,858.82 | 261.90 |
| Piramal Enterprises Ltd | 2,530.00 | 235.51 | 60,310.32 | 34.34 | 1.23 | 515.35 | 962.90 |
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Laurus Labs LtdSummary & Reports
Laurus Labs is a leading research and development (R&D) driven pharmaceutical company in India, with a leadership position in generic active pharmaceutical ingredients (APIs) for select, high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (P... More
Registered Office
Plot No 21 Jawaharlal Nehru,Pharma City Parawada,Visakhapatnam, Andhra Pradesh,531021
Tell. : +91-891-3061222
Website : http://www.lauruslabs.com
Email : secretarial@lauruslabs.com
Registrar Office
Karvy Selenium Tow-B, Nanakramguda, Hyderabad-500032 INDIA
Tell. : +91-40-67162222
Website : www.kfintech.com
Email : einward.ris@kfintech.com
Reports by laurus-labs-ltd-share-price
Latest Release by laurus-labs-ltd-share-price
Result Express
Laurus Labs Ltd's Q3FY19 consolidated net profit declines 48.9% yoy to Rs17.82cr : Misses Estimates
Jan 22, 2022 06:21 PM
The company’s consolidated revenue stood at Rs529.46cr, up 10.55% yoy but down 10% qoq.
Shareholding Snapshot
Loading ...
| Dec - 2021 | |
|---|---|
| Promoter | - |
| Foreign | 0.00% |
| Indian | 27.27% |
| Total Promoter | 27.27% |
| Non Promoter | - |
| Institutions | 28.98% |
| Non-Institutions | 43.76% |
| Total Non-Promoter | 72.73% |
| Custodian | 0.00% |
| Total | 100% |
Corporate Action
Purpose
Dividend
Annc. Date
28 Oct 2021
Effective. Date
17 Nov 2021
Divi. Type
Interim
Divi.(%)
40
Divi. Amt.
0.8
Board approved:Approved for the payment of interim dividend of Rs. 0.80/- ( 40/o) per equity share o... More
Purpose
Board Meeting
Exp. Date
28 Oct 2021
Annc. Date
20 Oct 2021
Quarterly Results & Interim DividendLaurus Labs Ltdhas informed BSE that the meeting of the Board of... More
